UPS
MCID: UND005
MIFTS: 66

Undifferentiated Pleomorphic Sarcoma (UPS)

Categories: Bone diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Undifferentiated Pleomorphic Sarcoma

MalaCards integrated aliases for Undifferentiated Pleomorphic Sarcoma:

Name: Undifferentiated Pleomorphic Sarcoma 52 58 6 17
Malignant Fibrous Histiocytoma 52 71
Ups 52 58
Malignant Fibrohistiocytic Tumors 52

Characteristics:

Orphanet epidemiological data:

58
undifferentiated pleomorphic sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (United States); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: any age;

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

MESH via Orphanet 44 D051677
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0334463
Orphanet 58 ORPHA2023
UMLS 71 C0334463

Summaries for Undifferentiated Pleomorphic Sarcoma

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 2023 Definition An aggressive sarcoma of soft tissues or bone that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture and occasional systemic features and is characterized by high local recurrence and significant metastasis . Epidemiology UPS ranks the 4th most common soft tissue sarcoma with a slight male preponderance. The incidence has been evaluated to be close to 0.8-1 new case per 100000 per year in one European series. Clinical description The tumor arises most commonly during the sixth and seventh decades of life. The most common sites of involvement include lower extremities (mainly thigh) followed by upper arms, retroperitoneum, viscera, head and neck (in childhood). Primary osseous UPS most commonly occurs in distal femur, proximal tibia, proximal femur and humerus. Patients may present pain, swelling / mass and pathological fractures. In the skin, UPS presents as a relatively painless, rapidly enlarging nodule. Anorexia, malaise, fever and weight loss are present in retroperitoneal and inflammatory forms of UPS. Most UPS recur locally; distant metastases are common (the most frequent is lung). Regional metastases are rare. Etiology UPS is thought to be derived from a primitive mesenchymal cell capable of differentiating into histiocytes, fibroblasts , myofibroblasts and osteoclasts. The etiology of the tumor remains unknown. Prior radiation therapy is a likely risk factor in some cases. Diagnostic methods Any tumor mass over 5 cm is suspected to be a sarcoma. Magnetic resonance imaging (MRI) is the imaging method of choice for limbs and shows a high signal on T2 weighted images. Histology of biopsy specimen prior to any treatment is crucial to reach diagnosis and shows pleomorphic spindle cell population with large atypical cells frequently exhibiting numerous irregular mitotic figures, associated regions of hemorrhage and necrosis, associated lymphohistiocytic infiltrate and invasion of dermis. Immunohistochemical staining is negative for S-100, HMB-45, CD34 and cytokeratin which assists in ruling out other soft tissue tumors. Most cases previously diagnosed as malignant fibrous histiocytoma have been reclassified into other histological types of sarcoma. Differential diagnosis When occurring in skin, UPS is difficult to differentiate from atypical fibroxanthoma or dermatofibrosarcoma protuberans (see this term). Histological differential diagnoses include leiomyosarcoma, rhabdomyosarcoma, lymphoma, and melanoma (see these terms). Management and treatment UPS should be referred to an expert/ reference center for primary biopsy, expert pathology review, and multidisciplinary treatment. Immediate surgery of a mass without knowledge of its histological nature is strongly discouraged because it is associated with an increased risk of death due to inappropriate resection and increased risk of relapse. UPS is best treated by wide surgical excision. Sometimes amputation may be necessary to remove the whole lesion. Adjuvant radiotherapy is given for high-grade, large (>5 cm), deep-seated tumors, in limb sparing surgeries and when negative margins are not obtained. For non-operable sarcomas, primary radiation therapy could be an option, but usually doxorubicin containing regimens are preferred options in first-line setting for locally irresectable and/or metastatic lesions. Chemotherapy (CHT) with ifosfamide, trabectedin, dacarbazine, pazopanib have demonstrated efficacy in UPS and are registered and available in most European Union countries. Prognosis A 5-year overall survival rate of 48% has been reported for patients with head and neck tumors versus 77% for patients with tumors arising on the trunk and extremities. The childhood variant appears have better prognosis. Visit the Orphanet disease page for more resources.

MalaCards based summary : Undifferentiated Pleomorphic Sarcoma, also known as malignant fibrous histiocytoma, is related to malignant skin fibrous histiocytoma and anus cancer. An important gene associated with Undifferentiated Pleomorphic Sarcoma is RECQL4 (RecQ Like Helicase 4), and among its related pathways/superpathways are HIV Life Cycle and Developmental Biology. The drugs Ifosfamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and lung, and related phenotypes are abnormality of the lower limb and abnormality of the peritoneum

Wikipedia : 74 Undifferentiated pleomorphic sarcoma, previously malignant fibrous histiocytoma, is a type of cancer,... more...

Related Diseases for Undifferentiated Pleomorphic Sarcoma

Diseases related to Undifferentiated Pleomorphic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 5644)
# Related Disease Score Top Affiliating Genes
1 malignant skin fibrous histiocytoma 32.9 MLANA KIT
2 anus cancer 31.4 PIK3CA KRAS KIT
3 ovarian clear cell carcinoma 31.4 PIK3CA MET KRAS
4 giant cell glioblastoma 31.4 PDGFRA IDH2 IDH1
5 carney triad 31.0 PDGFRA KIT
6 oligodendroglioma 30.9 PDGFRA NTRK1 IDH2 IDH1
7 retroperitoneal sarcoma 30.9 MLANA KIT
8 enchondroma 30.8 IDH2 IDH1
9 neurilemmoma 30.7 PDGFRA KIT EZR
10 chordoma 30.7 PDGFRA MET IDH1
11 leiomyosarcoma 30.6 PDGFRA MLANA KIT
12 differentiated thyroid carcinoma 30.6 NTRK1 MET KRAS
13 meningioma, familial 30.5 MLANA KIT IDH1 EZR
14 angiosarcoma 30.4 MLANA KRAS KIT
15 neurofibromatosis, type i 30.4 PDGFRA KIT
16 neurofibroma 30.3 PDGFRA MLANA KIT
17 intrahepatic cholangiocarcinoma 30.3 KRAS IDH2 IDH1
18 fibrosarcoma of bone 30.2 PDGFRA KIT
19 sarcoma 30.1 STAT3 PIK3CA PDGFRA MET KRAS KIT
20 hypereosinophilic syndrome 30.1 STAT3 PDGFRA KIT
21 malignant peripheral nerve sheath tumor 30.1 PDGFRA MLANA MET KIT
22 muscle cancer 30.1 PDGFRA MLANA KIT
23 mixed glioma 30.1 PDGFRA IDH2 IDH1
24 large cell carcinoma 30.0 PDGFRA KRAS KIT
25 carcinosarcoma 30.0 PIK3CA KRAS KIT
26 rhabdomyosarcoma 29.9 PDGFRA MET KRAS KIT EZR
27 gastrointestinal stromal tumor 29.9 PDGFRA MIR152 KRAS KIT
28 neurofibromatosis, type iv, of riccardi 29.9 PDGFRA KRAS KIT EZR
29 myeloid leukemia 29.8 STAT3 KRAS KIT IDH2 IDH1
30 cellular myxoid liposarcoma 29.8 PIK3CA KIT
31 gliosarcoma 29.7 PDGFRA IDH2 IDH1
32 cytogenetically normal acute myeloid leukemia 29.7 IDH2 IDH1
33 cerebellar astrocytoma 29.7 IDH2 IDH1
34 pulmonary vein stenosis 29.7 PDGFRA KIT
35 melanoma, uveal 29.7 MLANA MET KIT EZR
36 small cell carcinoma 29.6 PDGFRA KRAS KIT
37 colorectal adenocarcinoma 29.6 STAT3 KRAS KIT
38 adenocarcinoma 29.5 STAT3 PIK3CA MET KRAS KIT
39 myelofibrosis 29.5 STAT3 KIT IDH2 IDH1
40 mastocytosis 29.5 PDGFRA NTRK1 KIT
41 peripheral nervous system neoplasm 29.5 PRDM10 NTRK1 KIT
42 grade iii astrocytoma 29.5 PDGFRA IDH2 IDH1
43 mesenchymal cell neoplasm 29.4 PDGFRA NTRK1 MLANA KIT
44 hypereosinophilic syndrome, idiopathic 29.4 PDGFRA KIT
45 essential thrombocythemia 29.4 STAT3 KIT IDH2 IDH1
46 chondroblastic osteosarcoma 29.3 IDH2 IDH1 EZR
47 glioma 29.3 PIK3CA PDGFRA MET IDH2 IDH1
48 myelodysplastic syndrome 29.3 STAT3 KRAS KIT IDH2 IDH1
49 cervical squamous cell carcinoma 29.3 STAT3 PIK3CA KRAS
50 breast duct papilloma 29.3 IDH2 IDH1

Graphical network of the top 20 diseases related to Undifferentiated Pleomorphic Sarcoma:



Diseases related to Undifferentiated Pleomorphic Sarcoma

Symptoms & Phenotypes for Undifferentiated Pleomorphic Sarcoma

Human phenotypes related to Undifferentiated Pleomorphic Sarcoma:

58 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the lower limb 58 31 hallmark (90%) Very frequent (99-80%) HP:0002814
2 abnormality of the peritoneum 58 31 hallmark (90%) Very frequent (99-80%) HP:0002585
3 soft tissue sarcoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0030448
4 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
5 abnormality of the musculature 58 31 frequent (33%) Frequent (79-30%) HP:0003011
6 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
7 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
8 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
9 abnormality of the upper limb 58 31 occasional (7.5%) Occasional (29-5%) HP:0002817
10 abnormal test result 58 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.17 KIT MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.17 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.17 MET
4 Decreased substrate adherent cell growth GR00193-A-4 9.17 KIT MET NTRK1

MGI Mouse Phenotypes related to Undifferentiated Pleomorphic Sarcoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.38 AMPD2 CD74 EZR IDH1 KIT KRAS
2 immune system MP:0005387 10.32 AMPD2 CD74 EZR IDH1 KIT KRAS
3 mortality/aging MP:0010768 10.3 AMPD2 CD74 EZR IDH1 KIT KRAS
4 behavior/neurological MP:0005386 10.27 AMPD2 KIT KRAS LMNA MET NTRK1
5 hematopoietic system MP:0005397 10.26 AMPD2 CD74 EZR IDH1 KIT KRAS
6 digestive/alimentary MP:0005381 10.15 EZR KIT KRAS LMNA MET PDGFRA
7 integument MP:0010771 10.15 KIT KRAS LMNA MLANA NTRK1 PDGFRA
8 craniofacial MP:0005382 10.1 KIT KRAS LMNA MET PDGFRA RECQL4
9 limbs/digits/tail MP:0005371 10.08 IDH2 KIT KRAS LMNA MET NTRK1
10 muscle MP:0005369 10.03 KIT KRAS LMNA MET NTRK1 PDGFRA
11 neoplasm MP:0002006 10.01 IDH2 KIT KRAS MET PDGFRA PIK3CA
12 no phenotypic analysis MP:0003012 9.91 KIT KRAS MET MLANA NTRK1 PDGFRA
13 pigmentation MP:0001186 9.87 KIT KRAS LMNA MLANA NTRK1 PDGFRA
14 renal/urinary system MP:0005367 9.8 AMPD2 KIT KRAS LMNA MET PDGFRA
15 respiratory system MP:0005388 9.7 IDH1 KIT KRAS LMNA MET PDGFRA
16 skeleton MP:0005390 9.65 CD74 IDH1 IDH2 KIT KRAS LMNA
17 vision/eye MP:0005391 9.28 EZR KIT KRAS LMNA MET NTRK1

Drugs & Therapeutics for Undifferentiated Pleomorphic Sarcoma

Drugs for Undifferentiated Pleomorphic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
5
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
10
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
11 Olaratumab Approved, Investigational Phase 3 1024603-93-7
12
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
13
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
14 Immunosuppressive Agents Phase 3
15 Immunologic Factors Phase 3
16 Anti-Infective Agents Phase 3
17 Antirheumatic Agents Phase 3
18
Isophosphamide mustard Phase 3 0
19 Antimitotic Agents Phase 3
20 Etoposide phosphate Phase 3
21 Anti-Bacterial Agents Phase 2, Phase 3
22 Antibiotics, Antitubercular Phase 2, Phase 3
23 Topoisomerase Inhibitors Phase 2, Phase 3
24
Liposomal doxorubicin Phase 2, Phase 3 31703
25 Alkylating Agents Phase 2, Phase 3
26
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
27
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
28
Indinavir Approved Phase 2 150378-17-9 5362440
29
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
30
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
nivolumab Approved Phase 2 946414-94-4
33
Ipilimumab Approved Phase 2 477202-00-9
34
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
35
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
36
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
37
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
38
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
39
Pembrolizumab Approved Phase 2 1374853-91-4
40
Gemcitabine Approved Phase 2 95058-81-4 60750
41
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
42
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
43
Durvalumab Approved, Investigational Phase 2 1428935-60-7
44
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
45 Exatecan Investigational Phase 2 171335-80-1
46
Camptothecin Experimental Phase 2 7689-03-4
47 Soblidotin Investigational Phase 2 149606-27-9
48
Tremelimumab Investigational Phase 2 745013-59-6
49
protease inhibitors Phase 2
50 HIV Protease Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
4 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
5 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
6 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
12 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
13 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
15 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
18 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
19 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
20 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
21 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
22 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
23 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
24 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
25 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
26 Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF) Completed NCT00085475 Phase 2 imatinib mesylate
27 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
28 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
29 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
30 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
31 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
32 SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity Recruiting NCT03092323 Phase 2 Pembrolizumab
33 Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2
34 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Recruiting NCT03899805 Phase 2 Eribulin;Pembrolizumab
35 A Phase 1b Single Center Investigation of Safety/Efficacy of Nivolumab (Opdivo®) and ABI-009 (Nab-rapamycin) in Patients With Advanced Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Chondrosarcoma, Osteosarcoma and Ewing Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
36 A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Recruiting NCT02923778 Phase 2
37 A Phase I Study to Assess the Safety and Tolerability of Pembrolizumab in Combination With Fixed Rate Gemcitabine Chemotherapy in Patients With Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
38 A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
39 A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma Recruiting NCT04025931 Phase 2 chidamide and toripalimab
40 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting NCT02301039 Phase 2 Pembrolizumab
41 A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
42 A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
43 A Single-arm, Single-center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients Not yet recruiting NCT03946943 Phase 2 Anlotinib;Toripalimab
44 Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas Terminated NCT00740597 Phase 2
45 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Completed NCT02565758 Phase 1 ABBV-085
46 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
47 Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
48 Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen Completed NCT00020267 Phase 1 interleukin-2;MAGE-12 peptide vaccine;Montanide ISA-51
49 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
50 VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK] Unknown status NCT00900211

Search NIH Clinical Center for Undifferentiated Pleomorphic Sarcoma

Genetic Tests for Undifferentiated Pleomorphic Sarcoma

Anatomical Context for Undifferentiated Pleomorphic Sarcoma

MalaCards organs/tissues related to Undifferentiated Pleomorphic Sarcoma:

40
Bone, Breast, Lung, Heart, Skin, Thyroid, Brain

Publications for Undifferentiated Pleomorphic Sarcoma

Articles related to Undifferentiated Pleomorphic Sarcoma:

(show top 50) (show all 4014)
# Title Authors PMID Year
1
Surgical outcomes and prognostic factors of non-metastatic radiation-induced sarcoma of bone. 61
31703834 2020
2
What is an adequate margin for infiltrative soft-tissue sarcomas? 61
31627932 2020
3
Undifferentiated small round cell sarcoma in a young male: a case report. 61
32014859 2020
4
Free tibia and fibula-fillet-of-leg flap for pelvic ring reconstruction: A case report. 61
32022325 2020
5
Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. 61
31350181 2020
6
Pleomorphic malignant fibrous histiocytoma in bladder diverticulum. 61
31788429 2020
7
CT of primary undifferentiated pleomorphic sarcoma of small intestine with distant metastases presenting with intussusception. 61
31737145 2020
8
The Management of Head and Neck Sarcoma. 61
31934973 2020
9
Primary undifferentiated pleomorphic sarcoma (Malignant fibrous histiocytoma) of the lung: A case report. 61
31998481 2020
10
Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015. 61
31969161 2020
11
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. 61
31900276 2020
12
Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review. 61
31651522 2020
13
Systematic screening identifies a 2-gene signature as a high-potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma. 61
31742892 2020
14
Targeting glutamine metabolism slows soft tissue sarcoma growth. 61
31980651 2020
15
TGFβ and Hippo pathways cooperate to enhance sarcomagenesis and metastasis through the hyaluronan mediated motility receptor (HMMR). 61
31988250 2020
16
Uterine pleomorphic leiomyosarcoma with osteoclastic giant cells: Case report with peritoneal washing cytology and cell block study. 61
31932012 2020
17
Laryngeal Squamous Cell Carcinoma with Osteosarcomatous Differentiation and Involvement of Thyroid Cartilage Mimicking Sarcoma Arising from Thyroid Cartilage. 61
31873935 2019
18
Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study. 61
31825533 2019
19
Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth. 61
31478563 2019
20
A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases. 61
31520939 2019
21
Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profile. 61
31313299 2019
22
Prospective Evaluation of the Concordance of Commercial Circulating Tumor DNA Alterations with Tumor-Based Sequencing across Multiple Soft Tissue Sarcoma Subtypes. 61
31766329 2019
23
Is TLE1 Expression Limited to Synovial Sarcoma? Our Experience at Shifa International Hospital, Pakistan. 61
31893185 2019
24
Imaging Soft-tissue Sarcomas of the Head and Neck: A Tertiary Soft-tissue Sarcoma Unit Experience. 61
31704851 2019
25
Head and Neck Tumors: Management of Primary Undifferentiated Pleomorphic Sarcoma. 61
31857977 2019
26
Malignant fibrous histiocytoma amplified sequence 1 alleviates inflammation and renal fibrosis in diabetic nephropathy by inhibiting TLR4. 61
31696221 2019
27
An autopsy case of pulmonary artery intimal sarcoma: detailed observation of tumor and its related lesions in pulmonary arteries. 61
31437715 2019
28
Malignant fibrous histiocytoma arising from the renal capsule and gene mutation screening: A case report. 61
31641593 2019
29
Radiation-induced undifferentiated pleomorphic sarcoma of the breast: a rare but serious complication following breast-conserving therapy. A case report and literature review. 61
32007118 2019
30
Differing characteristics of cartilaginous lesions of the larynx. 61
31338576 2019
31
TP53 in bone and soft tissue sarcomas. 61
31276706 2019
32
Soft-tissue sarcoma in adolescents and young adults compared with older adults: A report among 5000 patients from the Scandinavian Sarcoma Group Central Register. 61
31287163 2019
33
Patterns of Care and Survival in Elderly Patients With Locally Advanced Soft Tissue Sarcoma. 61
31503061 2019
34
Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. 61
31342400 2019
35
G-CSF-producing Undifferentiated Pleomorphic Sarcoma Adjacent to the Ascending Colon and in the Right Iliopsoas Muscle: A Case Report and Review of the Literature. 61
31243197 2019
36
Effects of MFHAS1 on cognitive impairment and dendritic pathology in the hippocampus of septic rats. 61
31476310 2019
37
Surgical Treatment of Oral Cavity Nodular Fasciitis. 61
31609954 2019
38
Hypertensive Crisis during Microwave Ablation of Adrenal Neoplasms: A Retrospective Analysis of Predictive Factors. 61
31155498 2019
39
Identification of Novel Fusion Transcripts in Undifferentiated Pleomorphic Sarcomas by Transcriptome Sequencing. 61
31467233 2019
40
Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases. 61
31364245 2019
41
Spontaneous pancreatic undifferentiated pleomorphic sarcoma in a laboratory rat: A case report. 61
31773099 2019
42
Undifferentiated Pleomorphic Sarcoma of the Hand with Lung Metastases. 61
31523591 2019
43
[Atypical fibroxanthoma and pleomorphic dermal sarcoma]. 61
31468069 2019
44
Spindle cell liposarcoma with a TRIO-TERT fusion transcript. 61
30793229 2019
45
Treatment of spinal malignant fibrous histiocytoma, a case report and literature review. 61
30527900 2019
46
Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience. 61
30656606 2019
47
Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial. 61
31449140 2019
48
Undifferentiated Pleomorphic Sarcoma With Emperipolesis. 61
31436108 2019
49
Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas. 61
31443718 2019
50
[Ultrasound and MRI features of malignant fibrous histiocytoma of soft tissue]. 61
31533386 2019

Variations for Undifferentiated Pleomorphic Sarcoma

ClinVar genetic disease variations for Undifferentiated Pleomorphic Sarcoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RECQL4 NM_004260.3(RECQL4):c.1717C>T (p.Gln573Ter)SNV Likely pathogenic 620609 rs1483085748 8:145739734-145739734 8:144514350-144514350

Cosmic variations for Undifferentiated Pleomorphic Sarcoma:

9 (show top 50) (show all 649)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM101976974 XPO1 soft tissue,lower extremity,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 6
2 COSM87949760 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.871A>C p.K291Q 17:7673749-7673749 6
3 COSM87900565 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 6
4 COSM87906877 TP53 soft tissue,bone,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 6
5 COSM87897745 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 6
6 COSM87912393 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.577C>T p.H193Y 17:7674954-7674954 6
7 COSM87911884 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.856G>T p.E286* 17:7673764-7673764 6
8 COSM88205650 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.611A>G p.E204G 17:7674920-7674920 6
9 COSM87900604 TP53 soft tissue,NS,rhabdomyosarcoma,spindle cell c.637C>T p.R213* 17:7674894-7674894 6
10 COSM87918666 TP53 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 6
11 COSM87897711 TP53 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 6
12 COSM87938119 TP53 soft tissue,bone,leiomyosarcoma,NS c.512A>G p.E171G 17:7675100-7675100 6
13 COSM87897839 TP53 soft tissue,NS,rhabdomyosarcoma,pleomorphic c.701A>G p.Y234C 17:7674262-7674262 6
14 COSM87967612 TP53 soft tissue,arm,leiomyosarcoma,NS c.652G>A p.V218M 17:7674879-7674879 6
15 COSM87922564 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 6
16 COSM94086664 TOP1 soft tissue,lower extremity,leiomyosarcoma,NS c.1576G>C p.E526Q 20:41114093-41114093 6
17 COSM93617455 SUFU soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.780G>T p.E260D 10:102597163-102597163 6
18 COSM93992510 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 6
19 COSM84133785 RICTOR soft tissue,NS,rhabdomyosarcoma,pleomorphic c.2898-1G>T p.? 5:38952426-38952426 6
20 COSM86625172 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1004T>G p.L335* 13:48367558-48367558 6
21 COSM86633237 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.345C>G p.F115L 13:48342679-48342679 6
22 COSM93451505 RAC1 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 6
23 COSM96995108 PTPRT soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3415C>T p.R1139W 20:42106818-42106818 6
24 COSM96996279 PTPRT soft tissue,lower extremity,leiomyosarcoma,NS c.1201C>T p.R401W 20:42472515-42472515 6
25 COSM101931022 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 6
26 COSM101978164 PTPRD soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 6
27 COSM96843054 PTEN soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.697C>T p.R233* 10:87957915-87957915 6
28 COSM96842281 PTEN soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.389G>A p.R130Q 10:87933148-87933148 6
29 COSM96879218 PTEN soft tissue,retroperitoneum,leiomyosarcoma,NS c.1027-7T>C p.? 10:87965280-87965280 6
30 COSM90842465 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 6
31 COSM96437477 PIK3CG soft tissue,NS,rhabdomyosarcoma,spindle cell c.2638G>A p.E880K 7:106883041-106883041 6
32 COSM87210160 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 6
33 COSM87181562 PIK3CA soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 6
34 COSM87146468 PIK3CA soft tissue,retroperitoneum,leiomyosarcoma,NS c.1798G>A p.E600K 3:179219622-179219622 6
35 COSM101270110 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
36 COSM98770048 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 6
37 COSM97687376 NTRK3 soft tissue,NS,rhabdomyosarcoma,spindle cell c.492C>A p.C164* 15:88137534-88137534 6
38 COSM97660893 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1577C>A p.P526Q 15:88032865-88032865 6
39 COSM97675531 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452G>A p.S151N 15:88147347-88147347 6
40 COSM97107943 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 6
41 COSM97107326 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.181C>A p.Q61K 1:114713909-114713909 6
42 COSM97107359 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.182A>G p.Q61R 1:114713908-114713908 6
43 COSM98006136 NOTCH4 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2738C>G p.S913C 6:32210879-32210879 6
44 COSM86198080 NOTCH3 soft tissue,lower extremity,leiomyosarcoma,NS c.2741C>T p.P914L 19:15181627-15181627 6
45 COSM89882601 NKX2-1 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.404G>T p.R135M 14:36519044-36519044 6
46 COSM84820183 MYOD1 soft tissue,NS,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 11:17720147-17720147 6
47 COSM101146422 MYCL soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.740G>A p.R247H 1:39897817-39897817 6
48 COSM94449550 MTOR soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4799A>G p.E1600G 1:11144721-11144721 6
49 COSM85771827 MSH6 soft tissue,lower extremity,leiomyosarcoma,NS c.3991C>T p.R1331* 2:47806641-47806641 6
50 COSM94301542 MPL soft tissue,lower extremity,leiomyosarcoma,NS c.1880T>C p.L627P 1:43352744-43352744 6

Expression for Undifferentiated Pleomorphic Sarcoma

Search GEO for disease gene expression data for Undifferentiated Pleomorphic Sarcoma.

Pathways for Undifferentiated Pleomorphic Sarcoma

Pathways related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 STAT3 PIK3CA PDGFRA MET LMNA KRAS
2
Show member pathways
13.42 STAT3 PIK3CA PDGFRA MET KRAS KIT
3
Show member pathways
12.94 STAT3 PDGFRA NTRK1 MET KRAS KIT
4
Show member pathways
12.87 PIK3CA PDGFRA NTRK1 MET KRAS KIT
5
Show member pathways
12.81 STAT3 PIK3CA PDGFRA MET KRAS
6
Show member pathways
12.77 STAT3 PIK3CA PDGFRA NTRK1 KRAS
7
Show member pathways
12.73 PIK3CA PDGFRA MET KRAS KIT
8 12.68 PDGFRA NTRK1 MET KRAS KIT
9
Show member pathways
12.68 STAT3 PIK3CA PDGFRA NTRK1 KRAS KIT
10
Show member pathways
12.64 PIK3CA PDGFRA MET KRAS KIT
11
Show member pathways
12.62 STAT3 PIK3CA NTRK1 MET KRAS
12 12.59 STAT3 PIK3CA PDGFRA NTRK1 MET KRAS
13
Show member pathways
12.57 STAT3 PIK3CA PDGFRA MET KRAS
14
Show member pathways
12.53 PIK3CA PDGFRA NTRK1 MET KRAS KIT
15
Show member pathways
12.51 STAT3 PIK3CA PDGFRA KRAS
16 12.49 STAT3 MLANA KIT CD74
17
Show member pathways
12.49 STAT3 PIK3CA PDGFRA MET KRAS
18
Show member pathways
12.42 PIK3CA PDGFRA MET KRAS
19
Show member pathways
12.41 STAT3 PIK3CA MET KRAS
20
Show member pathways
12.31 PIK3CA PDGFRA KRAS KIT
21
Show member pathways
12.25 PIK3CA PDGFRA NTRK1 MET KRAS
22
Show member pathways
12.1 PDGFRA NTRK1 MET KRAS KIT
23 12.08 STAT3 PIK3CA MET KRAS EZR
24
Show member pathways
12 STAT3 PIK3CA PDGFRA KRAS
25
Show member pathways
12 STAT3 PIK3CA PDGFRA NTRK1 MET KRAS
26 11.99 STAT3 PIK3CA PDGFRA MIR152 MET KRAS
27 11.98 PDGFRA NTRK1 MET KIT
28
Show member pathways
11.92 PIK3CA PDGFRA NTRK1 MET LMNA KRAS
29 11.83 STAT3 PIK3CA KRAS
30
Show member pathways
11.77 STAT3 PIK3CA KRAS
31
Show member pathways
11.72 PIK3CA KRAS KIT
32 11.66 PDGFRA NTRK1 KRAS EZR
33
Show member pathways
11.57 STAT3 PIK3CA NTRK1
34
Show member pathways
11.35 STAT3 PIK3CA MET
35 11.23 STAT3 MET KRAS
36 11.01 PIK3CA PDGFRA NTRK1 MET KRAS KIT
37 10.93 PDGFRA NTRK1 MET KIT EZR
38
Show member pathways
10.76 IDH2 IDH1

GO Terms for Undifferentiated Pleomorphic Sarcoma

Cellular components related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 PDGFRA NTRK1 MET KIT CD74
2 receptor complex GO:0043235 8.92 PDGFRA NTRK1 MET KIT

Biological processes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.97 PIK3CA PDGFRA NTRK1 MET KIT
2 phosphorylation GO:0016310 9.91 STAT3 PIK3CA PDGFRA NTRK1 MET KIT
3 cytokine-mediated signaling pathway GO:0019221 9.85 STAT3 PIK3CA KRAS KIT
4 MAPK cascade GO:0000165 9.8 PDGFRA MET KRAS KIT
5 positive regulation of MAPK cascade GO:0043410 9.76 NTRK1 KIT CD74
6 positive regulation of protein kinase B signaling GO:0051897 9.76 PIK3CA PDGFRA MET KIT
7 peptidyl-tyrosine phosphorylation GO:0018108 9.71 PDGFRA NTRK1 MET KIT
8 liver development GO:0001889 9.7 PIK3CA MET KRAS
9 positive regulation of gene expression GO:0010628 9.63 STAT3 LMNA KRAS KIT EZR CD74
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.62 PDGFRA NTRK1 MET KIT
11 2-oxoglutarate metabolic process GO:0006103 9.58 IDH2 IDH1
12 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.56 STAT3 CD74
13 positive regulation of phospholipase C activity GO:0010863 9.54 PDGFRA KIT
14 energy homeostasis GO:0097009 9.54 STAT3 PIK3CA AMPD2
15 NADP metabolic process GO:0006739 9.51 IDH2 IDH1
16 isocitrate metabolic process GO:0006102 9.48 IDH2 IDH1
17 glyoxylate cycle GO:0006097 9.26 IDH2 IDH1
18 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.26 PIK3CA PDGFRA NTRK1 KIT
19 phosphatidylinositol-mediated signaling GO:0048015 8.92 PIK3CA PDGFRA NTRK1 EZR

Molecular functions related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.85 STAT3 NTRK1 MET IDH1 EZR CD74
2 nucleotide binding GO:0000166 9.72 PDGFRA NTRK1 MET KRAS KIT
3 protein tyrosine kinase activity GO:0004713 9.56 PDGFRA NTRK1 MET KIT
4 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH2 IDH1
5 isocitrate dehydrogenase activity GO:0004448 8.96 IDH2 IDH1
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 PDGFRA NTRK1 MET KIT

Sources for Undifferentiated Pleomorphic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....